Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other 1

Conditions

Obesity 7Endometrial Neoplasms 5Prostatic Neoplasms 2Overweight 2Endometrial Hyperplasia 2Diabetes Mellitus 2Breast Neoplasms 2Weight Loss 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Opioid-Related Disorders 1Lymphoma, Follicular 1Insulin Resistance 1Hyperplasia 1Colorectal Neoplasms 1

Interventions

Megestrol Acetate 7Medroxyprogesterone Acetate 4Progestins 3Metformin 3Tirzepatide 2Progesterone 2Letrozole 2Biopsy 2Atorvastatin 2semaglutide 1ricin A-GnRH conjugate 1exemestane 1estradiol, norethindrone drug combination 1Tamoxifen 1Rosuvastatin Calcium 1Resistance Training 1Pterocarpus marsupium 1Pharmacogenomic Variants 1Nutrition Assessment 1Magnetic Resonance Spectroscopy 1Levonorgestrel 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Hysteroscopy 1Hysterectomy 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Gonadotropin-Releasing Hormone 1Genetic Testing 1Everolimus 1Estrogen Replacement Therapy 1Cyproterone acetate, ethinyl estradiol drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Endometrial Hyperplasia × Tirzepatide × Clear all
NCT07078838 2026-06-04

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Not yet recruiting
40 enrolled
GynecologicOther

Endometrial Hyperplasia, Hyperplasia, Obesity, Endometrial Neoplasms

NCT07349641 2026-05-14

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
55 enrolled
Gynecologic

Endometrial Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡